Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study
Sponsor study identifier
observational
1,200
1 country
1
Study Start
January 1, 2024
Actual (reported)Primary Completion
October 10, 2024
Actual (reported)Study Completion
October 10, 2024
Actual (reported)The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccRCC patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 10, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2024
Actual (reported)October 10, 2024
Actual (reported)October 10, 2024
Actual (reported)October 20, 2024
Actual (reported)October 24, 2024
Actual (reported)Disease free survival
Defined as from surgery to tumor recurrence or follow-up deadline
"Baseline, immediately after the surgery", "Tumour recurrence or further follow-up", "Three months after surgery", "Six months after surgery", "Every year after surgery, at least follow-up 2years, up to 10 years"
Pathologically confirmed postoperative patients with renal clear cell carcinoma of TNM stage I-III
Renji Hospital
Shanghai, Shanghai Municipality, 200120, China
HE pathology sections of ccRCC postoperative tissues
1,200 participants (actual enrollment reported by the registry).
First Submitted
October 20, 2024
First Posted
October 24, 2024
Study Start
January 1, 2024
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
October 10, 2024
Actual (reported)Study Completion
October 10, 2024
Actual (reported)Last Updated
October 24, 2024
Record last verified: 2024-10
Data will be made available to interested research partners upon reasonable request to Zhaiwei or Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; the prerequisite for this is a data transfer agreement, approved by the legal departments of the requesting researcher and by all legal departments of the institutions that provided data for the study, and an ethics clearance.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: